Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection;Recomendaciones de GEAM/SPNS sobre el tratamiento de las alteraciones metabólicas y morfológicas en el paciente con infección por VIH

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 2, 2006, Pages 96-117

  Polo, Rosa ^a   Galindo, Ma José ^b   Martínez, Esteban ^c,w   Álvarez, Julia ^d   Arévalo, José Manuel ^e   Asensi, Víctor ^f   Cánoves, Dolores ^g   Cáncer, Emilia ^h   Collazos, Julio ⁱ   Estrada, Vicente ^j   Gómez Candela, Carmen ^k   Johnston, Susan ^l   Locutura, Jaime ^m   López Aldeguer, José ⁿ   Lozano, Fernando ^o   Miralles, Celia ^p   Muñoz Sanz, Agustín ^q   Ortega, Enrique ^g   Pascua, Javier ^r   Pedrol, Enric ^s   Pulido, Federico ^t   San Martín, Miguel ^k   Sanz, Jesús ^u   Viciana, Pompeyo ^v   Chamorro, Lourdes ^a   more..

^a Plan Nacional Sobre el Sida   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^e Centro de Cirugía Estética y Reconstructiva   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^h HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

ⁱ HOSPITAL DE GALDAKAO   (Spain)

^j HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^k HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^l Centro Dietética y Nutrición   (Spain)

^m HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

ⁿ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^o HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^p HOSPITAL XERAL CÍES   (Spain)

^q HOSPITAL INFANTA CRISTINA   (Spain)

^r Geriatric Service Hospital Ntra Sra de la Montaña Complejo Hospitalario de Cáceres   (Spain)

^s HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^t HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^u HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^v HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^w UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

Cardiovascular risk; Dyslipidemia; HIV; Insulin resistance

Indexed keywords

FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AIDS PATIENT; CARDIOVASCULAR RISK; DYSLIPIDEMIA; EARLY DIAGNOSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; METABOLIC DISORDER; PATHOPHYSIOLOGY; PATIENT CARE; PREVALENCE; REVIEW; SEXUAL DYSFUNCTION; TREATMENT PLANNING;

EID: 33645398120     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13085017     Document Type: Article

References (95)

1. Galli M, Polo R, Saint-Marc T, Walli R. Guidelines to describe morphologic and metabolic alterations (MMA) under ART: the Marrakech classification. Nutrition and Metabolic Disorders in HIV Infection; Vol 1; 2001;1:25-29.
2. Smith CJ, Levy I, Sabin CA, Kaya E, Johnson MA, Lipman MC. Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. HIV Med. 2004;5:88-92.
3. Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. Risk of diabetes in HIV infected veterans pre- and post- HAART and the role of HCV coinfection. Hepatology. 2004;40:115-9.
4. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603-8.
5. Moyle GJ. Bridging a gap: surgical management of HIV-associated lipoatrophy. AIDS Read. 2004;14:472-5.
6. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS. 2003;17 Suppl 1:S141-8.
7. Wohl DA. Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV infection and its therapies. Top HIV Med. 2004;12:89-93.
8. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, et al. Reversibility of lipoatropby in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18:1029-36.
9. McComsey G, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL Study. Clin Infect Dis. 2004;38:263-70.
10. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodistrophy. A randomized, controlled trial. Ann Intern Med. 2004;140:786-94.
11. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomized, double-blind, placebo-controlled trial. Lancet. 2004;363:429-38.
12. Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003;17:2471-7.
13. th Conference on Retroviruses on Opportunistic Infections; February 8-11, 2004; San Francisco, California. Abstract 80.
14. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000;284:472-7.
15. Driscoll SD, Meininger GE, Ljungquist K, Hadigan C, Torriani M, Klibanski A, et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS. 2004;18:465-73.
16. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, Brathwait CE, et al. Improve insuline sensitivity and fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr. 2002;31:163-70.
17. Sutinen J, Hakkiven AM, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Jarvinen A, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy - A randomized double-blind placebo-controlled study. Antivir Ther. 2003;8:199-207.
18. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markes of cardiovascular risk in human inmunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab. 2002;87:4611-5.
19. Schambelan M, Benson CA, Carr A, Currier JS, Michael P. Dubé, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an Internacional AIDS Society-USA Panel. JAIDS. 2002;31:257-75.
20. Gómez Candela C, De Cos Blanco AI, Mateo R, Castro E, Lorenzo A, Polo R. Alteraciones del metabolismo hidrocarbonado en el paciente VIH/SIDA. Nutrición Hospitalaria. 2002;17:147-53.
21. Castro E, De Cos A, Iglesias C, Gómez Candela C. Alteraciones endocrinometabólicas en pacientes VIH positivos. En: Manual de Nutrición y Sida. Madrid; 2000. p. 56-79.
22. Dube MP. Disorders of glucose metabolism in patients with human inmunodeficiency virus. Clin Infect Dis. 2000;31:1467-75.
23. th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, USA; 2004.
24. Iloeje U, Wu Y, Cislo P, Klleher T, Odeshoo L, Giordano M. Risk of Metabolic syndrome (metsyn) among Highly-treatment experienced HIV-infected patients - 48 week results from BMS studyAI 424045. In;2004;Bangkok; 2004.
25. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Adult AIDS Clinical Trials Group Cardiovascular Subcommitte; HIV Medical Association of the Infectious disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trial Group. Clin Infect Dis. 2003;37:613-27. Epub 2003 Aug 15.
26. Friis-Moler N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Data collection on adverse events of anti-HIV drugs (DAD) study group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
27. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS. 2003;17:851-9.
28. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholestrolaemia associated with protease inhibitor therapy. AIDS. 2001;15:1503-8.
29. Masana L. Recomendaciones farmacológicas. Fármacos hipolipemiantes. Interacciones farmacológicas. Guía de manejo de la dislipemia en pacientes infectados por el VIH. [Informes, Guías y Recomendaciones de la SEA] 2002 [Citado 1-12-2002]. Disponible en: http//:www.searteriosclerosis.org.
30. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease. [homepage on the internet] International Atherosclerosis Society, [update 2002 Dec 1]. Disponible en: http//www.searteriosclerosis.org
31. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-77.
32. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administred drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect. 2001;42:181-8.
33. Glesby MJ. Bone disorders in human immunodeficiency virus infection. Clin Infect Dis. 2003;37 Suppl 2:91-5.
34. Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;37 Suppl 2:101-5.
35. Buera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is dependent of antirretroviral therapy. AIDS. 2003;17:1917-23.
36. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS. 2004;18:475-83.
37. Mondy K, Yarashesky K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482-90.
38. Carr A. Lactic acidemia in infection with human immunodeficiency virus. Clin Infect Dis. 2003;36 Suppl 2:96-100.
39. AIDS Clinical Trials Group [homepage on the internet]. Hyperlactatemia acidosis. [updated 2002 Aug 13]. AACTG metabolic guides. Disponible en: http://aactg.s-3.com/metabolic/default.htm
40. Falcó V, Rodríguez D, Ribera E, Martínez E, Miró JM, Domingo P, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency Virus-infected patients: report f 12 cases and review of the literature. Clin Infect Dis. 2002;34:838-46.
41. Lozano F, Ramayo E, Corzo JE, Gómez-Mateos J. Hiperlactatemia sintomática en pacientes con infección por el virus de la inmunodeficiencia humana tratados con análoges de nucleósidos. Med Clin (Barc). 2001;117:36.
42. Soler A, Deig E, Ribell M, Pérez M, Pedrol E. Consultas urgentes por efectos secundarios del tratamiento antirretroviral y su manejo. En: Pedrol E, Soler A, editores. Urgencias y VIH. Granollers, Barcelona, 2004.
43. Iribarren JA, Labarga P, Rubio R, Berenguer J, Miro JM, Antela A, et al. Spanish GESIDA/National AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004). Enferm Infecc Microbiol Clin. 2004;22:561-3.
44. Pedrol E, Ribell M, Deig E, Villà MC, Miró O, Garrabou G, et al. Tratamiento de la hiperlactatemia sintomática y de la acidosis láctica en pacientes con infección por el virus de la inmunodeficiencia humana en tratamiento con inhibidores de la transcriptasa inversa análogos de los nucleósidos. Med Clin (Barc). 2005;125:201-4.
45. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV- infected adults: case-control study. Lancet. 2003;361:726-35.
46. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An update coronary risk profile. A statement for health professionals. Circulation. 1991;83:356-62.
47. The DAD Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
48. Grundy S, Cleeman J, Bairey N, Bryan H, Clark L, Hunninghake D, et al. Implications of recent clinical trial for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;100:227-39.
49. Hsue P, Giri K, Erickson S, MacGregor JS, Younis Y, Shergill A, et al. Clinical features of acute coronary syndromes in patients with human immunodefiency virus infection. Circulation. 2004;109:316-9.
50. th Conference on Retroviruses and opportunistic Infections; February 8-11, 2004; San Francisco, California [abstract 740].
51. Martínez E, Collazos J, Mayo J, Blanco MS. Sexual dysfunction with protease inhibitors. Lancet. 1999;353:810-1.
52. Collazos J, Martínez E, Mayo J, Ibarra S. Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy. AIDS. 2002;16:934-7.
53. Collazos J, Martínez E, Mayo J, Ibarra S. Sexual dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:322-6.
54. Collazos J, Mayo J, Martínez E, Ibarra S. Association between sexual disturbances and sexual hormones with specific antiretroviral drugs. AIDS. 2002;16:1294-5.
55. Collazos J, Mayo J, Martínez E, Ibarra S. Serum cortical in HIV-infected patients with and without highly active antiretroviral therapy. AIDS. 2003;17:123-5.
56. Collazos J, Ibarra S, Loureiro M. Cortisol serum levels and their relationship to certain antiretroviral drugs. Scand J Infect Dis. 2004;36:480-2.
57. Collazos J, Ibarra S, Mayo J. Thyroid hormones in HIV-infected patients in the highly active antiretroviral therapy era. Evidence of an interrelation between the thyroid axis and the immune system. AIDS. 2003;17:763-5.
58. Collazos J, Ibarra S, Martínez E, Mayo J. Serum prolactin concentrations in patients infected with human immunodeficiency virus. HIV Clin Trials. 2002;3:133-8.
59. Bruckert E, Giral P, Heshmati HM, Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther. 1996;21:89-94.
60. Catalan J, Meadows J. Sexual dysfunction in gay and bisexual men with HIV infection: evaluation, treatment and implications. AIDS Care. 2000;12:279-86.
61. Sollima S, Osio M, Alciati A, d'Arminio Monforte A, Zucconi M, Maga T, et al. Protease inhibitors and male impotence. XIII International Conference on AIDS. Durban, South Africa, July 9-14, 2000 [Abstract WePeB4216].
62. Schrooten W, Colebunders R, Youle M, Molenberghs G, Dedes N, Koitz G, et al. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS. 2001;15:1019-23.
63. Pavón de Paz I, Vega Piñero B, Monereo Megías S. Clínica de la obesidad. En: Moreno B, Monereo S, Álvarez J, editores. La obesidad: epidemia del siglo XXI. Ed. Idepsa; 1999;10:149-68.
64. Detsky AS, McLaughin JH, Barker JP, Johnston N, Whittaker S, Mendelson RA, et al. What is subjective global assessment of nutritional status? JPEN. 1987;11:8-13.
65. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
66. Dubé MP, Sprecher D. Lipid abnormalities. Clin Infect Dis. 2003;36 Suppl 2:79-83.
67. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, De Souza R, et al. Effects of a dietary portfolio of Cholesterol-lowering foods vs lovastatin on serum levels and C-reactive protein. JAMA. 2003;290:502-10.
68. Gelato MC. Insulin and carbohydrate dysregulation. Clin Infect Dis. 2003;36 Suppl 2:91-5.
69. Clinical Practice Recommendations. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care. 2000;23 Suppl 1:43-6.
70. Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;36 Suppl 2:101-5.
71. Johnston S. Prevención, dietas y tratamiento nutricional. Consejos dietéticos, suplementos nutricionales y vitamínicos. En: Polo Rodríguez R, editor. Manual de Nutrición y Sida. Ed. Nilo Industria Gráfica, S.A.; 2002;2:180-225.
72. WHOQOL Group Measuring Quality of life: the development of the World Health Organisation Quality of Life instrument (WHOQOL). Genève: OMS; 1993. p. 10.
73. Brashers DE, Neidig JL, Goldsmith DJ. Social support and management of uncertainty for people living with HIV or AIDS. Health Commun. 2004;16:305-31.
74. Sandelowski M, Lambe C, Barroso J. Stigma in HIV-positive women j. Health Psychol. 2004;23:94-100.
75. Heckman TG, Anderson ES, Sikkema KJ, Kochman A, Kalichman SC, Anderson T. Emotional distress in nonmetropolitan persons living with HIV disease enrolled in a telephone-delivered, coping improvement group intervention. S Afr Med J. 2003;93:928-31.
76. a). Trastornos Mentales y del Comportamiento. Madrid: Meditor; 1992.
77. DSM-IV-TR. Manual diagnóstico y estadístico de los trastornos mentales. Texto Revisado. Barcelona: Masson; 2002.
78. Theodore Millon (con R. Davis). Trastornos de la personalidad Más allá del DSM-IV. Barcelona: Masson; 1998.
79. Cruess DG, Douglas SD, Pettito JM, Leserman J, Ten Have T, Gettes D, et al. Association of depression, CD8+ T lymphocytes, and natural killer cell activity: implications for morbidity and mortality in human immunodefiency virus disease. Curr Psychiatry Rep. 2003;5:445-508.
80. Hughes J, Jelsma J, Maclean E, Darder M, Tinise X. The health related quality of life of people living with HIV/AIDS. Disabil Rehabil. 2004;26:371-6.
81. Beck A. Cognitive therapy and the emotional disorders. New York: International Universities Press; 1976.
82. Maslach C. The Burnt-Out syndrome and patient care. En: Garfield C, editor. Stress and survival: The emotional realities of life-threatening illness. St. Louis: Mosby; 1999.
83. Goossens ME, Vlaeyen JW, Hidding A, Kole-Snijders A, Evers SM. Treatment expectancy affects the outcome of cognitive-behavioural interventions in chronic pain. Clin J Pain. 2005;21:18-26; discussion 69-72.
84. Cánoves L, Ortega E. Tratamiento psicológico cognitivo en pacientes VIH/SIDA VII Congreso N. Psiquiatr Act Esp de Psiquiatr. 2003;31:46.
85. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis. 2002;35:1219-30.
86. Saag MS, Powderly WG, Schambelan M, Benson CA, Carr A, Currier JS, et al. Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: summary of selected trials. Topics HIV Med. 2002;10:47-51.
87. Arévalo JM, Del Pino V. Tratamiento quirúrgico integral del paciente con síndrome lipodistrófico asociado al VIH. En: Polo R, coord. Actualización en el tratamiento de la lipodistrofia y alteraciones metabólicas. Madrid; 2003. p. 76-85.
88. Casavantes LC, Gottlieb M. Bio-Alcamid, a high-volume injectable prosthesis for facial reconstruction in HIV-related lipoatrophy: report on 100 patients. Antivir Ther. 2004;9:L37.
89. Serra MS, Oyafuso LK. Soft tissue augmentation with polymethymethacrylate (PMMA) for correction of lipodystrophy related body fat atrophy. Antivir Ther. 2004;9:L31.
90. Christensen LH, Breiting V, Aasted A, Jorgensen A, Kebuladze I. Long term effects of polyacrylamide hydrogel in human breast tissue. Plat Reconstr Surg. 2003;101:1883-90.
91. White DJ. Ultrasound assisted liposuction in 2002. Operatives techniques in plastic and reconstructive surgery. 2002;8:133-9.
92. Polo R, Ortiz M, Babe J, Martínez S, Madrigal P, González-Munoz M. The effects of polylactic acid in the therapy for the lipoatrophy of the face. Antiviral Therapy. 2001;6 Suppl 4:68.
93. Guaraldi G, Orlando G, De Fazio D, Vigo M, De Lorenzi I, Rottino A, et al. Autologous fat transfer for the treatment of HIV-related face lipoatrophy: a long follow-up experience. Antiviral Therapy. 2004;9:L50.
94. Arévalo JM, Del Pino V. Reconstruction of the buttocks in adult patients with chronic HIV-1 infection by means of submuscular anatomical implants of cohesive silicone gel. Nutr Metab Dis HIV Infect. 2003;2:250-6.
95. Arévalo JM, Del Pino V. Ultrasound assisted liposuction in adult patients with HIV-1 associated lipodystrophy syndrome. Nutr Metab Dis HIV Infect. 2003;2:98-105.